CLAIMS:

1. A pharmaceutical composition comprising:
(a) an isolated uricase comprising an amino acid sequence of SEQ ID NO. 7; and
(b) a pharmaceutically acceptable carrier;
wherein the uricase is conjugated with a polymer.

2. A pharmaceutical composition comprising:
(a) a uricase comprising an amino acid sequence of SEQ ID NO. 8; and
(b) a pharmaceutically acceptable carrier
wherein the uricase is conjugated with a polymer.

3. The pharmaceutical composition of claim 1, wherein the uricase further comprises amino terminal amino acid, wherein the amino terminal amino acid is alanine, glycine, proline, serine, or threonine.

4. The pharmaceutical composition of any one of claims 1 and 2, wherein the polymer is selected from the group consisting of poly(ethylene glycol), dextran, polypropylene glycol, hydroxypropylmethyl cellulose, carboxymethylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol.

5. The pharmaceutical composition of claim 4 comprising 2-12 polyethylene glycol moieties on each uricase subunit.

6. The pharmaceutical composition of claim 5 comprising 3-10 polyethylene glycol moieties on each uricase subunit.

7. The pharmaceutical composition of claim 4, wherein each polyethylene glycol moiety has a molecular weight between about 1 kD and about 100 kD.

8. The pharmaceutical composition of claim 7, wherein each polyethylene glycol moiety has a molecular weight between about 1 kD and about 50 kD.

9. The pharmaceutical composition of claim 8, wherein each polyethylene glycol moiety has a molecular weight between about 5 kD and about 20 kD.